Heat Shock Proteins and Cancer

Müfide Öncel 1 *
More Detail
1 Konya Numune Hastanesi Biyokimya Laboratuarı
* Corresponding Author
EUR J BASIC MED SCI, Volume 2, Issue 1, pp. 16-23. https://doi.org/10.21601/ejbms/9171
Download Full Text (PDF)


Heat shock proteins are a group of proteins in all living cells. They are synthesized due to various environmental factors, not only against high-temperature. These proteins are preserved in all prokaryotes and eukaryotes. Heat shock proteins play in part many pathological conditions such as autoimmune diseases, infectious diseases, heart diseases and cancer. Their effects on cancer development are provided by suppression of anticancer mechanisms such as apoptosis, cellular aging, activated immune system and increased metastatic gene expression. The inhibitors of heat shock proteins have been involved in the treatment of cancer due to their targeting cancer specific proteins and inhibitions of autonomous growth.


Öncel M. Heat Shock Proteins and Cancer. Eur J Basic Med Sci. 2012;2(1):16-23. https://doi.org/10.21601/ejbms/9171


  • Ritossa F. Discovery of the heat shock response. Cell stress chaperones 1996;1(2):97-8.
  • Derek SW, Hector RW. Heat shock response and acute lung injury. Radical Biology & Medicine 2007; 42: 1–14.
  • Calderwood SK, Khaleque A, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences 2006; 3(31):164-72.
  • Kiang JG, Tsokos GC. Heat Shock Protein 70 kDa: Molecular Biology, Biochemistry, and Physiology Pharmacol Ther 1998;2(80):183–201.
  • Pratt WB, Toft DO. Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70- Based Chaperone Machinery. Exp Biol Med 2003; 228(2): 111-33.
  • Schlesinger MJ. How the cell copes with stress and the function of heat shock proteins. Pediatr Res 1994; 36: 1–6.
  • Hut HMJ, Kampinga HM, Sibon OCM. Hsp70 protects mitotic cells against heatinduced centrosome damage and division abnormalities. Mol Biol Cell 2005; 16: 3776–85.
  • Beere HM. ‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641–51.
  • Nylandsted J. Gyrd-Hansen M, Danielewicz A et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004;200:425–35.
  • Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10:86–103.
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
  • Sherman M, Multhoff G. Heat Shock Proteins in Cancer. Ann NY Acad Sci 2007;1113:192–201.
  • Sen T, Sen N, Brait M. et al. DNp63a Confers Tumor Cell Resistance to Cisplatin through the AKT1 Transcriptional Regulation. Cancer Res 2011; 71(3):1167-76.
  • Taira T, Sawai M, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y. J Biol Chem 1999; 274(34): 24270-9.
  • Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, Tsuchida N. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ 1995; 6(1): 1-8.
  • Madden SL, Galella EA, Zhu J, Bertelsen AH, Beaudry GA. SAGE Transcript Profiles for p-53 dependent growth regulation. Oncogene 1997; 15: 1079-85.
  • Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002; 22(24): 8659-68.
  • Agoff SN, Hou J, Linzer DI, Wu B. Regulation of the human hsp70 promoter by p53. Science 1993; 259(5091): 84-7.
  • Khaleque MA, Bharti A, Sawyer D. ve ark. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 2005; 24(43): 6564-73.
  • Lindquist S, Craig EA. The heat shock proteins. Annu Rev Genet 1988; 22: 631–7.
  • Jolly C. Morimoto RI. Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death. Jour Nat Cancer Institute 2000; 92( 19): 1564-72.
  • Pırkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J 2001; 15: 1118-31.
  • Volloch VZ, Sherman MY. Oncogenic potential of Hsp72. Oncogene 1999; 18: 3648 -51.
  • Barnes JA, Dix DJ, Collins BW, Luft C, Allen JW. Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress & Chaperones 2001;6(4):316–32.
  • Diehl JA, Yang W, Ronald A, Xiao RH, Emili A. Hsc70 Regulates Accumulation of Cyclin D1 and Cyclin D1-Dependent Protein Kinase. Mol Cel Biol 2003; 23(5): 1764-74.
  • Kaur J, Ralhan R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int J Cancer 2000; 85(1): 1-5.
  • Yaglom JA, Gabai VL, Sherman MY. High Levels of Heat Shock Protein Hsp72 in Cancer Cells Suppress Default Senescence Pathways. Cancer Res 2007; 67: 2373-81.
  • Hayflick L. Cell biology of aging. Fed Proc 1979; 38(5): 1847-50.
  • Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 12967-87.
  • Perez-Sala D, Rebollo A. Novel aspects of Ras proteins biology: regulation and Implications. Cell Death and Differentiation 1999; 6: 722-8.
  • Blyth K, Stewart M, Bell M. ve ark. Sensitivity to mycinduced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene 2000; 19: 773-82.
  • Ferbeyre G, Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GH, Lowe SW. Oncogenic ras and p53 Cooperate to Induce Cellular Senescence. Mol Cell Biol 2002; 22(10): 3497–508.
  • Trost TM, Lausch EU, Fees SA. Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma. Cells Cancer Res 2005; 65: 840-49.
  • Chen Z, Trotman LC, Shaffer D. ve ark. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725–30.
  • Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003; 22: 9007–21.
  • Eischen CM, Weber JD, Roussel MF. Disruption of the ARFMdm2- p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13: 2658-69.
  • Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jäättelä M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005; 19(5): 570-82.
  • Daugaard M, Kirkegaard-Sørensen T, Ostenfeld MS et al. Regulated Guardian of Lysosomal Stability in Human Cancer Lens Epithelium-Derived Growth Factor Is an Hsp70-2. Cancer Res 2007; 67: 2559-67.
  • Garrido C, Schimitt E, Cande C, Vahsen N, Parcillier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2: 579–84.
  • Landry J, Hout J. Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Biochem Cell Biol 1995; 73: 703–7.
  • Piotrowicz RS, Hicklley E, Levin EG. Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. Faseb J 1998; 12: 1481–90.
  • Lopes LB, Flynn C, Komalavilas P, Panitch A, Brophy CM, Seal BL. Inhibition of HSP27 Phosphorylation by a Cellpermeant MAPKAP Kinase 2 Inhibitor. Biochem Biophys Res Commun 2009; 382(3): 535–9.
  • Shin KD, Lee MY, Shin DS et al. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 2005; 80: 41439–48.
  • Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006; 25: 2987–98.
  • Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419–23.
  • Pratt W, Galigniana MD, Harrell JM, Defranco BD. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004; 16: 857–72.
  • Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8: 55–61.
  • Nimmanapalli R, O’Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17 demethoxygeldanamycin lowers Bcr–Abl levels and induces apoptosis and differentiation of Bcr–Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799–804.
  • Peng X, Guo X, Borkan SC et al. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Cem 2005; 280: 13148-52.
  • Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 2010; 10: 225.
  • Beere HM. ‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis. Journal of Cell Science 2004; 117: 2641- 51.
  • Calderwood SK. Heat shock proteins in breast cancer progression-asuitable case for treatment? Int J Hyperthermia 2010; 26(7): 681–5.
  • Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 as a Negative Regulator of Cytochrome c Release. Mol Cell Biol 2002; 22(3): 816-34.
  • Nelson DA, White E. Exploiting different ways to die. Genes Dev 2004; 18(11): 1223-6.
  • Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23(16): 2746- 56.
  • Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003; 283(1): 1-16.
  • Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 2003; 300:1142-5.
  • Soti C, Csermely P. Chaperones come of age Cell Stress & Chaperones 2002; 7(2): 186–90.
  • Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120: 513–22.
  • Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004; 10: 47–51.
  • Ergün MA, Replikatif Yaşlanma, Hücresel Senesens ve Apoptozis: Sonuçları ve Hastalıklardaki Önemi. Turkiye Klinikleri J Med Sci 2008; 28: S21-6.
  • Zhou J, Schmid T, Frank R, Brüne B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 2004; 279(14): 13506-13.
  • Sun J, Liao JK. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2004; 24(12): 2238-44.
  • Pfosser A, Thalgott M, Büttner K et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res 2005; 65(3): 728-36.
  • Hoang AT, Huang J, Rudra-Ganguly N et al. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 2000; 156(3): 857-64.
  • Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004; 3(9): 1098-100.
  • Price JT, Quinn JMV, Sims NA et al. The heat shock protein 90 inhibitor, 17-allylamino-17 demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65: 4929–38.
  • Calderwood SK, Theriault JR, Gong J. Message in a bottle: Role of the 70-kDa heat shock protein family in antitumor immunity. Eur J Immunol 2005; 35: 2518–27.
  • Asea A, Kraeft SK, Kurt-Jones EA et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 200; 6(4): 435-42.
  • Giffard RG, Han R-Q, Emery JF, Duan M, Pittet JF. Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia - the complex roles of Heat Shock Protein 70. Anesthesiology 2008; 109(2): 339–48.
  • Vishal C, Kumar JU, Swamy CVB, Nandini R et al. Repercussion of Mitochondria Deformity Induced by Anti-Hsp90 Drug 17AAG in Human Tumor Cells. Drug Target Insights 2011; 5: 11–32.
  • Marissa V, Powers, Clarke PA, Workman P. Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis. Cancer Cell 2008; 14: 250–62.
  • Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer cell 2003; 3: 213-7.
  • Smith JR, Workman P. Targeting the cancer chaperone HSP90. Cancer 2007; 4(4): 219-27.
  • Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu Chaperone Complex Vaccine Induces Protective Immunity Against Spontaneous Mammary Tumors in HER-2/neu Transgenic Mice. J Immunol 2003; 171: 4054-61.
  • Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395–425.
  • Calderwood SK. Chaperones and slow death-immunotherapy. Trends Biothecnol 2005; 23(2): 57.